Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm IONIC Immuno-Oncology Trial Commences


• Ethics Approval received for IONIC-1 clinical trial, with trial to commence immediately in Australian hospitals
• IONIC-1 to test combination of Veyonda® with blockbuster Bristol Myers Squibb drug, Opdivo® (nivolumab)
• Aim is to use Veyonda to overcome resistance to drugs such as Opdivo
• Success should expand multi-billion dollar drug sector considerably and deliver major NOX shareholder value

Sydney 19 March 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that the IONIC-1 trial supported by Noxopharm and Bristol Myers Squibb (BMS) received final ethics approval to start recruiting patients.

The IONIC-1 trial (previously announced on 9 November 2020) is a Phase 1b trial in approximately 30 cancer patients, combining Veyonda® with the BMS immune checkpoint inhibitor, Opdivo® (nivolumab), for the treatment of a range of tumour types.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.